TransThera Sciences (Nanjing). Inc. (HK:2617)
:2617
Want to see HK:2617 full AI Analyst Report?
2617 Stock Chart & Stats
HK$69.20
--
Market closed
HK$69.20
--
Day’s Range― - ―
52-Week RangeHK$20.20 - HK$679.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)4.21M
Market Cap
HK$10.98B
Enterprise ValueHK$0.00
Total Cash (Recent Filing)HK$489.14M
Total Debt (Recent Filing)HK$1.65M
Price to Earnings (P/E)―
Beta2.63
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding312,687,680
10 Day Avg. Volume2,613,813
30 Day Avg. Volume4,211,017
Financial Highlights & Ratios
PEG Ratio-13.39
Price to Book (P/B)96.58
Price to Sales (P/S)0.00
P/FCF Ratio-158.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageThe company's very low debt levels materially reduce refinancing and interest-rate risk, giving management flexibility in a capital-intensive development cycle. Over 2-6 months, low leverage supports runway and lowers fixed obligations, improving resilience while R&D progresses.
Biopharma R&D FocusA core therapeutic discovery/development model is structurally valuable: high barriers to entry, IP protection, and the potential for large payoffs from successful clinical milestones. Over months, R&D progress and pipeline value can materially change long-term prospects if clinical advancement occurs.
Improving Cash Flow TrendSequential improvement in free cash flow indicates the company is making operating or capex adjustments that reduce burn. Sustained improvement over several quarters would lower future external funding needs and signal operational discipline during the development phase.
Bears Say
Pre‑Revenue OperationsBeing effectively pre-revenue with no material product sales means the company has no operating cash inflows to offset R&D spending. Over the medium term this necessitates continual financing and leaves outcomes highly binary on clinical or partnership milestones.
Persistent Cash BurnLarge, recurring negative operating and free cash flows imply ongoing dilution or debt raises are likely unless commercial revenue emerges. Persistent cash burn constrains strategic optionality, increases financing risk, and pressures long-term sustainability absent clinical or licensing catalysts.
Eroding Asset BaseA declining equity and asset base reflects accumulated losses and reduced financial cushions. Continued erosion diminishes balance-sheet flexibility to fund trials or absorb setbacks, raising the probability of dilutive financings or partnership dependence over the next several months.
TransThera Sciences (Nanjing). Inc. News
2617 FAQ
What was TransThera Sciences (Nanjing). Inc.’s price range in the past 12 months?
TransThera Sciences (Nanjing). Inc. lowest stock price was HK$20.20 and its highest was HK$679.50 in the past 12 months.
What is TransThera Sciences (Nanjing). Inc.’s market cap?
TransThera Sciences (Nanjing). Inc.’s market cap is HK$10.98B.
When is TransThera Sciences (Nanjing). Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were TransThera Sciences (Nanjing). Inc.’s earnings last quarter?
Currently, no data Available
Is TransThera Sciences (Nanjing). Inc. overvalued?
According to Wall Street analysts TransThera Sciences (Nanjing). Inc.’s price is currently Overvalued.
Does TransThera Sciences (Nanjing). Inc. pay dividends?
TransThera Sciences (Nanjing). Inc. does not currently pay dividends.
What is TransThera Sciences (Nanjing). Inc.’s EPS estimate?
TransThera Sciences (Nanjing). Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TransThera Sciences (Nanjing). Inc. have?
TransThera Sciences (Nanjing). Inc. has 312,687,680 shares outstanding.
What happened to TransThera Sciences (Nanjing). Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TransThera Sciences (Nanjing). Inc.?
Currently, no hedge funds are holding shares in HK:2617
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TransThera Sciences (Nanjing). Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
TransThera Sciences (Nanjing). Inc.
TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor for the treatment of drug-resistant, relapsed, or refractory cancers. It also develops a pipeline of clinical stage product candidates and a preclinical stage product candidate. TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and changed its name to TransThera Sciences (Nanjing), Inc. in July 2021. The company was incorporated in 2014 and is headquartered in Nanjing, China.
Technical Analysis
Genscript Biotech
―
Zai Lab Ltd
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---